Envestnet Asset Management’s Cabaletta Bio CABA Stock Holding History

Envestnet Asset Management’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25,540	Closed	-$35.4K	–	4442
2025 Q1	$35.4K	Sell	25,540 -13,364	-34%	-$28.5K	﹤0.01%	4311
2024 Q4	$88.3K	Sell	38,904 -9,166	-19%	-$32.2K	﹤0.01%	4218
2024 Q3	$227K	Buy	48,070 +18,044	+60%	+$104K	﹤0.01%	3965
2024 Q2	$225K	Sell	30,026 -2,538	-8%	-$31.1K	﹤0.01%	3866
2024 Q1	$556K	Sell	32,564 -517	-2%	-$11.1K	﹤0.01%	3369
2023 Q4	$751K	Sell	33,081 -42,284	-56%	-$711K	﹤0.01%	3109
2023 Q3	$1.15M	Buy	75,365 +49,904	+196%	+$682K	﹤0.01%	2708
2023 Q2	$329K	Buy	25,461 +4,568	+22%	+$49.6K	﹤0.01%	3442
2023 Q1	$173K	Buy	+20,893	New	+$196K	﹤0.01%	3688

Other funds holding CABA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Envestnet Asset Management's CABA Position: Q2 2025 in Review

Envestnet Asset Management sold out of Cabaletta Bio (CABA) in Q2 2025, closing a stake of 25,540 shares — an estimated $35.4K sold.

Envestnet Asset Management first reported a position in CABA in Q1 2023 and held it in 9 quarters. The position peaked at $1.15M in Q3 2023. 86 funds tracked by Wall St. Rank hold CABA as of Q2 2025.

Envestnet Asset Management reported no remaining Cabaletta Bio position as of Q2 2025 after selling out during the quarter.
Envestnet Asset Management sold 25,540 Cabaletta Bio shares in Q2 2025, an estimated $35.4K.
Envestnet Asset Management first reported a position in Cabaletta Bio in Q1 2023 and held it in 9 quarters.
Envestnet Asset Management's Cabaletta Bio position peaked at $1.15M in Q3 2023.
86 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.